Medicamen Biotech Share Price

446.15-10.66 (-2.34%)
Volume: 70,530

Closed
Last Updated On: 25 Apr, 2025, 03:31 PM IST

STOCK SCORE

ETPrime Only

Medicamen Biotech Share Price

446.15-10.66 (-2.34%)
Volume: 70,530

Medicamen Bio share price insights

View All

Employee & Interest Expense
Company has spent 2.45% of its operating revenues towards interest expenses and 16.77% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -33.72% as compared to Nifty Smallcap 100 which gave a return of 61.05%. (as of last trading session)
Stock Returns vs Nifty Pharma
Stock generated -33.72% return as compared to Nifty Pharma which gave investors 60.2% return over 3 year time period. (as of last trading session)
Medicamen Bio Share Price Update
Medicamen Biotech Ltd. share price moved down by -2.34% from its previous close of Rs 456.80. Medicamen Biotech Ltd. stock last traded price is 446.15
Share Price Value
Today/Current/Last 446.15445.15
Previous Day 456.80455.80

Share Price	Value
Today/Current/Last	446.15445.15
Previous Day	456.80455.80

InsightsMedicamen Bio

Do you find these insights useful?

hate it
meh
love it

Key Metrics

PE Ratio

(x)

72.19

EPS - TTM

(₹)

6.18

MCap

(₹ Cr.)

567.26

Sectoral MCap Rank

PB Ratio

(x)

2.81

Div Yield

(%)

0.22

Face Value

(₹)

10.00

Beta

VWAP

(₹)

454.49

52W H/L

(₹)

630.00 / 375.05

Medicamen Bio Share Price Returns

1 Day	-2.34%
1 Week	-5.84%
1 Month	-1.57%
3 Months	-4.79%
1 Year	5.7%
3 Years	-35.26%
5 Years	N.A.

ET Stock ScreenersTop Score Companies

Check whether Medicamen Bio belongs to analysts' top-rated companies list?

View Stock Screeners

Medicamen Bio News & Analysis

View all Medicamen Bio Share News & Announcements

Medicamen Bio Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

View Stock Score on a 10-point scale
See ratings on Earning, Fundamentals, Valuation, Risk & Price
Check stock performance

JOIN ET PRIME

Medicamen Bio Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

Medicamen Bio Financials

Insights

Employee & Interest Expense
Company has spent 2.45% of its operating revenues towards interest expenses and 16.77% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

Quarterly \| Annual	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Total Income	45.28	45.03	43.63	47.89	47.33
Total Income Growth (%)	0.55	3.20	-8.88	1.17	7.35
Total Expenses	40.65	42.04	41.37	43.34	43.41
Total Expenses Growth (%)	-3.30	1.60	-4.55	-0.16	6.62
EBIT	4.64	3.00	2.26	4.54	3.92
EBIT Growth (%)	54.68	32.51	-50.20	15.92	16.23
Profit after Tax (PAT)	2.92	1.46	1.35	2.13	2.03
PAT Growth (%)	100.63	7.79	-36.50	4.82	37.46
EBIT Margin (%)	10.24	6.66	5.18	9.49	8.28
Net Profit Margin (%)	6.45	3.23	3.10	4.44	4.29
Basic EPS (₹)	2.30	0.71	0.63	1.61	1.60

Quarterly \| Annual	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Total Income	41.28	43.13	42.06	45.55	45.04
Total Income Growth (%)	-4.29	2.56	-7.67	1.14	4.20
Total Expenses	37.07	38.87	38.36	39.96	40.38
Total Expenses Growth (%)	-4.62	1.31	-3.99	-1.04	5.39
EBIT	4.21	4.27	3.69	5.59	4.66
EBIT Growth (%)	-1.31	15.50	-33.95	20.11	-5.13
Profit after Tax (PAT)	2.52	2.27	2.26	3.10	2.77
PAT Growth (%)	11.17	0.52	-27.25	12.18	-8.16
EBIT Margin (%)	10.20	9.89	8.78	12.28	10.34
Net Profit Margin (%)	6.11	5.26	5.37	6.81	6.14
Basic EPS (₹)	1.98	1.78	1.78	2.45	2.19

Quarterly \| Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	181.63	143.33	117.17	113.47	127.44
Total Revenue Growth (%)	26.72	22.33	3.26	-10.96	0.93
Total Expenses	168.56	126.28	99.07	97.08	109.46
Total Expenses Growth (%)	33.47	27.47	2.06	-11.32	0.66
Profit after Tax (PAT)	10.93	14.84	14.90	12.13	13.29
PAT Growth (%)	-26.36	-0.36	22.82	-8.74	10.52
Operating Profit Margin (%)	9.74	14.17	16.88	15.48	14.77
Net Profit Margin (%)	6.09	10.53	12.90	10.76	10.59
Basic EPS (₹)	7.50	11.92	12.19	9.93	10.94

Quarterly \| Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	174.69	140.35	117.17	110.90	119.25
Total Revenue Growth (%)	24.47	19.78	5.65	-7.00	-5.55
Total Expenses	157.80	123.01	99.06	94.15	102.65
Total Expenses Growth (%)	28.28	24.18	5.22	-8.28	-5.60
Profit after Tax (PAT)	13.30	15.00	14.91	12.49	12.26
PAT Growth (%)	-11.36	0.64	19.38	1.86	1.94
Operating Profit Margin (%)	12.33	14.69	16.89	16.17	14.63
Net Profit Margin (%)	7.71	10.88	12.91	11.33	10.44
Basic EPS (₹)	10.50	12.04	12.20	10.22	10.09

All figures in Rs Cr, unless mentioned otherwise

View Details

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Assets	294.55	278.52	225.69	194.01	181.28
Total Assets Growth (%)	5.76	23.41	16.33	7.02	32.72
Total Liabilities	87.57	85.10	79.22	61.12	60.07
Total Liabilities Growth (%)	2.89	7.42	29.63	1.75	20.23
Total Equity	206.98	193.41	146.47	132.89	121.22
Total Equity Growth (%)	7.02	32.05	10.22	9.63	39.92
Current Ratio (x)	1.89	1.98	1.69	1.80	1.84
Total Debt to Equity (x)	0.15	0.13	0.17	0.13	0.08
Contingent Liabilities	-	-	-	-	-

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Assets	294.21	276.78	225.70	192.47	176.46
Total Assets Growth (%)	6.30	22.63	17.27	9.07	29.19
Total Liabilities	85.01	82.99	77.66	58.12	53.98
Total Liabilities Growth (%)	2.43	6.86	33.62	7.67	8.05
Total Equity	209.21	193.80	148.04	134.35	122.48
Total Equity Growth (%)	7.95	30.91	10.19	9.69	41.38
Current Ratio (x)	1.85	1.96	1.70	1.84	1.93
Total Debt to Equity (x)	0.14	0.13	0.16	0.13	0.08
Contingent Liabilities	8.94	8.56	5.85	4.73	6.35

All figures in Rs Cr, unless mentioned otherwise

View Details

Insights

Decrease in Cash from Investing
Company has used Rs 5.56 cr for investing activities which is an YoY decrease of 5.4%. (Source: Consolidated Financials)

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash flow from Operating Activities	-6.74	-6.29	4.11	12.77	12.80
Net Cash used in Investing Activities	-5.56	-5.88	-8.47	-17.81	-37.29
Net Cash flow from Financing Activities	6.31	29.13	4.30	5.84	19.06
Net Cash Flow	-5.99	16.95	-0.07	0.80	-5.43
Closing Cash & Cash Equivalent	14.79	20.78	3.82	3.89	3.09
Closing Cash & Cash Equivalent Growth (%)	-28.84	443.27	-1.69	25.80	-63.70
Total Debt/ CFO (x)	-4.57	-3.84	5.93	1.36	0.78

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash flow from Operating Activities	-0.25	-3.50	4.81	13.29	11.71
Net Cash used in Investing Activities	-8.71	-7.54	-8.47	-18.12	-39.35
Net Cash flow from Financing Activities	3.14	27.67	4.39	5.68	21.36
Net Cash Flow	-5.82	16.63	0.73	0.85	-6.29
Closing Cash & Cash Equivalent	14.62	20.44	3.81	3.08	2.23
Closing Cash & Cash Equivalent Growth (%)	-28.48	435.87	23.68	38.12	-73.79
Total Debt/ CFO (x)	-120.17	-6.91	5.06	1.30	0.85

All figures in Rs Cr, unless mentioned otherwise

View Details

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Return on Equity (%)	5.28	7.77	10.17	9.12	10.96
Return on Capital Employed (%)	8.32	10.19	12.74	12.40	14.86
Return on Assets (%)	3.71	5.32	6.60	6.25	7.33
Interest Coverage Ratio (x)	5.59	9.01	18.04	16.41	32.63
Asset Turnover Ratio (x)	0.63	0.56	0.55	58.09	69.23
Price to Earnings (x)	44.64	56.18	52.91	54.05	16.61
Price to Book (x)	2.35	4.35	5.37	4.91	1.82
EV/EBITDA (x)	20.48	31.62	31.94	33.33	10.82
EBITDA Margin (%)	13.70	18.69	21.88	17.72	16.77

Annual	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Return on Equity (%)	6.35	7.78	10.06	9.29	10.00
Return on Capital Employed (%)	10.03	10.31	12.61	12.52	13.62
Return on Assets (%)	4.51	5.42	6.60	6.48	6.94
Interest Coverage Ratio (x)	6.46	9.10	18.05	16.74	30.21
Asset Turnover Ratio (x)	0.60	0.55	0.55	57.22	66.49
Price to Earnings (x)	36.76	55.56	52.91	52.36	18.02
Price to Book (x)	2.33	4.30	5.31	4.86	1.80
EV/EBITDA (x)	17.76	31.31	31.92	32.78	11.62
EBITDA Margin (%)	16.40	19.29	21.89	18.46	16.76

Financial InsightsMedicamen Bio

Income (P&L)
Cash Flow

- Employee & Interest Expense
  Company has spent 2.45% of its operating revenues towards interest expenses and 16.77% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
- Decrease in Cash from Investing
  Company has used Rs 5.56 cr for investing activities which is an YoY decrease of 5.4%. (Source: Consolidated Financials)

Do you find these insights useful?

hate it
meh
love it

Medicamen Bio Technicals

Stock doesn't have any Buy/Sell Signals.
Price Analysis Data details are not available.
Pivot Levels
R1 R2 R3 PIVOT S1 S2 S3
Classic - - - - - - -
Average True Range
5 DAYS 14 DAYS 28 DAYS
ATR - - -

	R1	R2	R3	PIVOT	S1	S2	S3
Classic	-	-	-	-	-	-	-

	5 DAYS	14 DAYS	28 DAYS
ATR	-	-	-

Medicamen Bio Peer Comparison

CHART
TABLE

Insights

Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -33.72% as compared to Nifty Smallcap 100 which gave a return of 61.05%. (as of last trading session)
Stock Returns vs Nifty Pharma
Stock generated -33.72% return as compared to Nifty Pharma which gave investors 60.2% return over 3 year time period. (as of last trading session)

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Medicamen Bio Stock Performance	-2.34	-5.84	-1.57	-4.79	5.70	-35.26	0.00
Wanbury Ltd Stock Performance	-7.58	-2.88	0.90	9.47	61.29	215.12	1060.45
Kilitch Drug Stock Performance	-2.64	-1.50	-2.62	3.74	-0.69	77.83	226.88
Nectar Lifesc Stock Performance	-4.48	0.09	-4.72	-40.73	-33.34	-23.00	52.20
Ind-Swift Labs Stock Performance	-6.17	-7.58	-9.03	-26.92	-35.26	18.22	279.76
Add More

Insights

Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -33.72% as compared to Nifty Smallcap 100 which gave a return of 61.05%. (as of last trading session)
Stock Returns vs Nifty Pharma
Stock generated -33.72% return as compared to Nifty Pharma which gave investors 60.2% return over 3 year time period. (as of last trading session)

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Medicamen Bio	72.19	2.74	5.28	8.32	3.71	16.79	9.74	5.29	7.50	1.89	0.15	-4.57
Wanbury Ltd	19.10	30.00	200.26	46.34	16.29	13.43	10.41	9.72	17.10	0.74	3.94	27.64
Kilitch Drug	28.46	3.16	8.28	14.37	6.08	30.33	16.37	8.79	9.17	2.27	0.18	-216.31
Nectar Lifesc	30.12	0.48	0.46	8.65	0.22	3.13	6.25	0.29	0.22	1.50	0.59	2.83
Ind-Swift Labs	2.03	0.52	45.19	26.09	36.13	13.07	19.22	32.90	71.24	2.99	0.02	-0.10
Add More

Annual Ratios (%)

Choose from Peers

Albert David
Medico Remedies
Zim Laboratories
Venus Remedies
Brooks Labs

Choose from Stocks

See All Parameters

Peers InsightsMedicamen Bio

Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -33.72% as compared to Nifty Smallcap 100 which gave a return of 61.05%. (as of last trading session)
Stock Returns vs Nifty Pharma
Stock generated -33.72% return as compared to Nifty Pharma which gave investors 60.2% return over 3 year time period. (as of last trading session)

Do you find these insights useful?

hate it
meh
love it

Medicamen Bio Shareholding Pattern

Loading...
Showing Medicamen Bio Shareholding as on Mar 2025
Category Mar 2025 Dec 2024 Sep 2024 Jun 2024
Promoters 43.16 42.99 42.99 42.99
Pledge 0.00 0.00 0.00 0.00
FII 0.12 0.06 0.06 0.06
DII 0.69 0.87 1.17 1.17
Mutual Funds 0.00 0.00 0.00 0.00
Others 56.03 56.08 55.77 55.77
Showing Shareholding as on Mar 2025
Category No. of Shares Percentage % Change QoQ
Promoters 54,87,095 43.16 % 0.16
Pledge 0 0.00 % 0.00
FII 14,638 0.12 % 0.05
DII 88,000 0.69 % -0.18
MF 76 0.00 % 0.00
Others 71,24,867 56.03 % -0.04

Category	Mar 2025	Dec 2024	Sep 2024	Jun 2024
Promoters	43.16	42.99	42.99	42.99
Pledge	0.00	0.00	0.00	0.00
FII	0.12	0.06	0.06	0.06
DII	0.69	0.87	1.17	1.17
Mutual Funds	0.00	0.00	0.00	0.00
Others	56.03	56.08	55.77	55.77

Category	No. of Shares	Percentage	% Change QoQ
Promoters	54,87,095	43.16 %	0.16
Pledge	0	0.00 %	0.00
FII	14,638	0.12 %	0.05
DII	88,000	0.69 %	-0.18
MF	76	0.00 %	0.00
Others	71,24,867	56.03 %	-0.04

Medicamen Bio MF Ownership

MF Ownership details are not available.

Medicamen Bio Corporate Actions

Meeting Date	Announced on	Purpose	Details
Mar 26, 2025	Mar 03, 2025	EGM	-
Feb 26, 2025	Feb 21, 2025	Board Meeting	Preferential issue of shares
Feb 11, 2025	Feb 04, 2025	Board Meeting	Quarterly Results
Nov 14, 2024	Nov 07, 2024	Board Meeting	Quarterly Results
Sep 25, 2024	Aug 16, 2024	AGM	Rs.1.0000 per share(10%)Final Dividend & A.G.M.

Type	Dividend	Dividend per Share	Ex-Dividend Date	Announced on
Final	10%	1.0	Sep 19, 2024	May 29, 2024
Final	10%	1.0	Sep 20, 2023	Aug 11, 2023
Final	10%	1.0	Sep 19, 2022	May 25, 2022
Final	10%	1.0	Sep 16, 2021	Jun 28, 2021
Final	5%	0.5	Sep 17, 2020	Jun 30, 2020

No other corporate actions details are available.

About Medicamen Bio

Medicamen Biotech Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 567.26 Crore) operating in Pharmaceuticals sector. Medicamen Biotech Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2024. Show More

Executives
Auditors

RB
Rahul Bishnoi
Chairman
RM
Rajesh Madan
Chief Executive Officer
AK
Ashwani Kumar Sharma
Non Executive Director
SB
Sanjay Bansal
Non Executive Director
SK
Suresh Kumar Singh
Non Executive Director
VK
Vimal Kumar Shrawat
Non Executive Director
AK
Arun Kumar
Independent Director
HP
Harish Pande
Independent Director
RK
Ravi Kumar Bansal
Independent Director
SB
Sangeeta Bishnoi
Independent Director
SD
Sumita Dwivedi
Independent Director
PS
Pratap Singh Rawat
Chief Financial Officer
PC
Parul Choudhary
Co. Secretary & Compl. Officer
Show More
Rai Qimat & Associates

Industry

Pharma - Indian

Key Indices Listed on

Address

1506, Chiranjiv Tower,43, Nehru Place,New Delhi, Delhi - 110019

Contact

cs@medicamen.com

http://www.medicamen.com

More Details

FAQs about Medicamen Bio share

1. What's the Medicamen Bio share price today?
As on 25 Apr, 2025, 03:42 PM IST Medicamen Bio share price is down by 2.34% basis the previous closing price of Rs 458.45. Medicamen Bio share price is Rs 446.15. Return Performance of Medicamen Bio Shares:
- 1 Week: Medicamen Bio share price moved down by 5.84%
- 1 Month: Medicamen Bio share price moved down by 1.57%
- 3 Month: Medicamen Bio share price moved down by 4.79%
2. What are the Medicamen Bio quarterly results?
Total Revenue and Earning for Medicamen Bio for the year ending 2024-03-31 was Rs 181.63 Cr and Rs 10.93 Cr on Consolidated basis. Last Quarter 2024-12-31, Medicamen Bio reported an income of Rs 45.28 Cr and profit of Rs 2.92 Cr.
3. Who are the key owners of Medicamen Bio stock?
Following are the key changes to Medicamen Bio shareholding:
- Promoter holding has gone up from 42.99 (30 Jun 2024) to 43.16 (31 Mar 2025)
- Domestic Institutional Investors holding have gone down from 1.17 (30 Jun 2024) to 0.69 (31 Mar 2025)
- Foreign Institutional Investors holding has gone up from 0.06 (30 Jun 2024) to 0.12 (31 Mar 2025)
- Other investor holding has gone up from 55.77 (30 Jun 2024) to 56.03 (31 Mar 2025)
4. What is the PE & PB ratio of Medicamen Bio?
The PE ratio of Medicamen Bio stands at 73.92, while the PB ratio is 2.9.
5. What is the CAGR of Medicamen Bio?
The CAGR of Medicamen Bio is 12.31.
6. What are the returns for Medicamen Bio share?
Return Performance of Medicamen Bio Shares:
- 1 Week: Medicamen Bio share price moved down by 5.84%
- 1 Month: Medicamen Bio share price moved down by 1.57%
- 3 Month: Medicamen Bio share price moved down by 4.79%
7. Who is the CEO of Medicamen Bio?
Rajesh Madan is the Chief Executive Officer of Medicamen Bio
8. What is the market cap of Medicamen Bio?
Medicamen Bio share has a market capitalization of Rs 567.26 Cr. Within Pharmaceuticals sector, it's market cap rank is 81.
9. What is 52 week high/low of Medicamen Bio share price?
Medicamen Bio share price saw a 52 week high of Rs 630.00 and 52 week low of Rs 375.05.
10. Who's the chairman of Medicamen Bio?
Rahul Bishnoi is the Chairman of Medicamen Bio
11. What dividend is Medicamen Bio giving?
An equity Final dividend of Rs 1 per share was declared by Medicamen Biotech Ltd. on 29 May 2024. So, company has declared a dividend of 10% on face value of Rs 10 per share. The ex dividend date was 19 Sep 2024.
12. How can I quickly analyze Medicamen Bio stock?
Key Metrics for Medicamen Bio are:
- PE Ratio of Medicamen Bio is 72.19
- Price/Sales ratio of Medicamen Bio is 2.72
- Price to Book ratio of Medicamen Bio is 2.81
13. Who are the peers for Medicamen Bio in Pharmaceuticals sector?
Top 10 Peers for Medicamen Bio are Medico Remedies Ltd., Albert David Ltd., Ind-Swift Laboratories Ltd., Wanbury Ltd., Zim Laboratories Ltd., Kilitch Drugs(I) Ltd., Lyka Labs Ltd., Nectar Lifesciences Ltd., Venus Remedies Ltd. and Brooks Laboratories Ltd.

Trending in Markets

Top Gainers As on 03:59 PM | 25 Apr 2025

SBI Life1,695.10

86.90 (5.41%)

Dr Lal Pathlabs2,911.20

123.00 (4.42%)

Atul6,414.50

182.00 (2.93%)

Mphasis2,538.60

70.50 (2.86%)

Navin Fluorine4,448.70

108.60 (2.51%)

Top Losers As on 03:59 PM | 25 Apr 2025

Motilal Oswal694.90

-61.11 (-8.09%)

Angel One2,328.40

-170.20 (-6.82%)

Reliance Power41.36

-3.01 (-6.79%)

DB Realty177.35

-12.82 (-6.74%)

GRSE1,616.80

-112.50 (-6.51%)

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.

BrowseCompanies:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

1 2 3 4 5 6 7 8 9

ETPrime

Medicamen Biotech Share Price

Medicamen Biotech Share Price

Medicamen Bio share price insights

InsightsMedicamen Bio

Key Metrics

Key Metrics

Medicamen Bio Share Price Returns

ET Stock ScreenersTop Score Companies

Medicamen Bio News & Analysis

Medicamen Bio Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Medicamen Bio Share Recommendations

Medicamen Bio Financials

Insights

Insights

Financial InsightsMedicamen Bio

Medicamen Bio Technicals

Pivot Levels

Average True Range

Medicamen Bio Peer Comparison

Insights

Insights

Ratio Performance

Peers InsightsMedicamen Bio

Medicamen Bio Shareholding Pattern

Medicamen Bio MF Ownership

Medicamen Bio Corporate Actions

About Medicamen Bio

Executives

Auditors

More Details

FAQs about Medicamen Bio share

Trending in Markets

Top Gainers As on 03:59 PM | 25 Apr 2025

Top Losers As on 03:59 PM | 25 Apr 2025

Medicamen Bio Quick Links

Equity Quick Links

More from Markets

1 Day	-2.33%
1 Week	-6.52%
1 Month	-2.58%
3 Months	-5.09%
1 Year	6.08%
3 Years	-35.58%
5 Years	70.26%